ArticleCureus2026
VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Auricular Chondritis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory disorder caused by somatic UBA1 mutations in hematopoietic stem and progenitor cells. It typically presents in older males with treatment-refractory systemic inflammation and hematologic abnormalities. We report a case of a 92-year-old male who presented with auricular chondritis and other systemic symptoms, including inflammatory arthritis, conjunctivitis, and a diffuse rash. Laboratory evaluation revealed macrocytic anemia and elevated inflammatory markers, with largely negative autoimmune serologies aside from a mildly elevated rheumatoid factor. Bone marrow analysis showed cytoplasmic vacuolization of myeloid and erythroid precursors, and genetic testing identified a UBA1 p.Met41Thr pathogenic variant, confirming the diagnosis of VEXAS syndrome. Treatment with oral prednisone, monthly tocilizumab infusions, and supportive epoetin alfa-epbx led to significant clinical improvement. This case underscores the importance of considering VEXAS syndrome in elderly male patients presenting with unexplained systemic inflammation, chondritis, and cytopenias, and highlights the critical roles of early recognition, multidisciplinary evaluation, and timely genetic testing in diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.